Revisiting the mechanisms of ACE inhibitory peptides from food proteins

Trends in Food Science and Technology

Volumn 69, Issue , 2017, Pages 214-219

  Wu, Jianping ^a,b   Liao, Wang ^b   Udenigwe, Chibuike C ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

ACE inhibition; ACE2; Antihypertension; Bioactive peptides; Cardiovascular disease; Endothelial function; Inflammation; Metabolic syndrome; Vascular oxidation

Indexed keywords

BIOCHEMISTRY; BLOOD PRESSURE; ENZYMES; METABOLISM; PATHOLOGY; PEPTIDES;

ACE INHIBITION; ACE2; ANTI-HYPERTENSION; BIOACTIVE PEPTIDES; CARDIO-VASCULAR DISEASE; ENDOTHELIAL FUNCTION; INFLAMMATION; METABOLIC SYNDROMES;

PROTEINS;

EID: 85024926621     PISSN: 09242244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tifs.2017.07.011     Document Type: Note

References (73)

1. Alghamri, M.S., Weir, N.M., Anstadt, M.P., Elased, K.M., Gurley, S.B., Morris, M., Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. Journal of Cardiovascular Pharmcology and Therapeutics 18 (2013), 138–151.
2. Beltrami, L., Zingale, L.C., Carugo, S., Cicardi, M., Angiotensin-converting enzyme inhibitor-related angioedema: How to deal with it. Expert Opinion on Drug Safety 5 (2006), 643–649.
3. Blake, G.J., Ridker, P.M., Novel clinical markers of vascular wall inflammation. Circulation Research 89 (2001), 763–771.
4. Cai, H., Harrison, D.G., Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circulation Research 87 (2000), 840–844.
5. Cicero, A.F.G., Gerocarni, B., Laghi, L., Borghi, C., Blood pressure lowering effect of lactotripeptides assumed as functional foods: A meta-analysis of current available clinical trials. Journal of Human Hypertension 25 (2011), 425–436.
6. 1 receptor blockers in the treatment of arterial hypertension. American Journal of Therapeutics 10 (2003), 401–408.
7. Díez-Freire, C., Vázquez, J., Correa de Adjounian, M.F., Ferrari, M.F.R., Yuan, L., Silver, X., et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiological Genomics 27 (2006), 12–19.
8. Donnelly, R., Angiotensin-converting enzyme-inhibitors and insulin sensitivity-metabolic effects in hypertension, diabetes, and heart-failure. Journal of Cardiovascular Pharmcology 20 (1992), S38–S44.
9. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research 87 (2000), e1–e9.
10. Ehlers, P.I., Nurmi, L., Turpeinen, A.M., Korpela, R., Vapaatalo, H., Casein-derived tripeptide Ile-Pro-Pro improves angiotensin-(1-7)- and bradykinin-induced rat mesenteric artery relaxation. Life Sciences 88 (2011), 206–211.
11. Fekete, A.A., Givens, D.I., Lovegrove, J.A., The impact of milk proteins and peptides on blood pressure and vascular function: A review of evidence from human intervention studies. Nutrition Research Reviews 26 (2013), 177–190.
12. Fernandez-Musoles, R., Castello-Ruiz, M., Arce, C., Manzanares, P., Ivorra, M.D., Salom, J.B., Antihypertensive mechanism of lactoferrin-derived peptides: Angiotensin receptor blocking effect. Journal of Agricultural and Food Chemistry 62 (2013), 173–181.
13. Fichtlscherer, S., Breuer, S., Zeiher, A.M., Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: Further evidence for the existence of the “vulnerable” patient. Circulation 110 (2004), 1926–1932.
14. FitzGerald, R.J., Murray, B.A., Walsh, D.J., Hypotensive peptides from milk proteins. The Journal of Nutrition 134 (2004), 980S–988S.
15. Foëx, P., Sear, J., Hypertension: Pathophysiology and treatment. Continuing Education in Anaesthesia, Critical Care & Pain 4 (2004), 71–75.
16. Fujita, H., Suganuma, H., Usui, H., Kurahashi, K., Nakagiri, R., Sasaki, R., et al. Vasorelaxation by Casomokinin L, a derivative of h-Casomorphin and Casoxin D, is mediated by NK1 receptor. Peptides 17 (1996), 635–639.
17. Fujita, H., Usui, H., Kurahashi, K., Yoshikawa, M., Isolation and characterization of ovokinin, a bradykinin B1 agonist peptide derived from ovalbumin. Peptides 16 (1995), 785–790.
18. Galle, J., Quaschning, T., Seibold, s., Wanner, C., Endothelial dysfunction and inflammation: What is the link?. Kidney International 84 (2003), S45–S49.
19. Geleijnse, J.M., Engberink, M.F., Lactopeptides and human blood pressure. Current Opinion in Lipidology 21 (2010), 58–63.
20. Halcox, J.P., Schenke, W.H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M.A., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106 (2002), 653–658.
21. Hall, J.E., Granger, J.P., do Carmo, J.M., da Silva, A.A., Dubinion, J., George, E., et al. Hypertension: Physiology and pathophysiology. Journal of Comparative Physiology 2 (2012), 2393–2442.
22. Hernández-Ledesma, B., del Mar Contreras, M., Recio, I., Antihypertensive peptides: Production, bioavailability and incorporation into foods. Advances in Colloid and Interface Science 165 (2011), 23–35.
23. Hirota, T., Nonaka, A., Matsushita, A., Uchida, N., Ohki, K., Asakura, M., et al. Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart and Vessels 26 (2011), 549–556.
24. Ijas, H., Collin, M., Finckenberg, P., Pihlanto-Leppälä, A., Korhonen, H., Korpla, R., et al. Antihypertensive opioid-like milk peptide-lactorphin: Lack of effect on behavioral tests in mice. International Dairy Journal 14 (2004), 201–205.
25. Jakala, P., Pere, E., Lehtinen, R., Turpeinen, A., Korpela, R., Vapaatalo, H., Cardiovascular activity of milk casein-derived tripeptides and plant sterols in spontaneously hypertensive rats. Journal of Physiology Pharmacology 60 (2009), 11–20.
26. Jose, P.A., Raj, D., Gut microbiota in hypertension. Current Opinion in Nephrology and Hypertension 24 (2015), 403–409.
27. Karbach, S.H., Schönfelder, T., Brandão, I., Wilms, E., Hörmann, N., Jäckel, S., et al. Gut microbiota promote angiotensin II–induced arterial hypertension and vascular dysfunction. Journal of the American Heart Association, 5, 2016 e003698.
28. Keidar, S., Kaplan, M., Gamliel-Lazarovich, A., ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovascular Research 73 (2007), 463–469.
29. Korhonen, H., Pihlanto, A., Bioactive peptides: Production and functionality. International Dairy Journal 16 (2006), 945–960.
30. Kulemina, L.V., Ostrov, D., Prediction of off-target effects on angiotensin converting enzyme 2. Journal of Biomolecular Screening 16 (2011), 878–885.
31. Lahera, V., Goicoechea, M., de Vinuesa, S.G., Miana, M., de las Heras, N., Cachofeiro, V., et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Current Medicinal Chemistry 14 (2007), 243–248.
32. Landmesser, U., Harrison, D.G., Drexler, H., Oxidant stress - a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. European Journal of Clinical Pharmacology 62 (2006), 13–19.
33. Lo, J., Patel, V.B., Wang, Z., Levasseur, J., Kaufman, S., Penninger, J.M., et al. Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar–Kyoto rats and spontaneously hypertensive rats. Experimental Physiology 98 (2013), 109–122.
34. Maes, W., Van Camp, J., Vermeirssen, V., Hemeryck, M., Ketelslegers, J.M., Schrezenmeir, J., et al. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regulatory Peptides 118 (2004), 105–109.
35. Majumder, K., Chakrabarti, S., Davidge, S.T., Wu, J., Structure and activity study of egg protein ovotransferrin derived peptides (IRW and IQW) on endothelial inflammatory response and oxidative stress. Journal of Agricultural and Food Chemistry 61 (2013), 2120–2129.
36. Majumder, K., Chakrabarti, S., Morton, J., Sareh, P., Kaufman, S., Davidge, S.T., et al. Egg-derived tri-peptide IRW exerts antihypertensive effects in spontaneously hypertensive rats. PLoS One, 8, 2013, e82829.
37. Majumder, K., Chakrabarti, S., Morton, J., Sareh, P., Kaufman, S., Davidge, S.T., et al. Egg-derived ACE-inhibitory peptides IQW and LKP reduce blood pressure in spontaneously hypertensive rats. Journal of Functional Foods 13 (2015), 50–60.
38. Majumder, K., Liang, G., Chen, Y., Guan, L.L., Davidge, S.T., Wu, J., Egg ovotransferrin derived ACE inhibitory peptide IRWincreases ACE 2 but decreases pro-inflammatory genes expression in mesenteric artery of spontaneously hypertensive rats. Molecular Nutrition and Food Research 59 (2015), 1735–1744.
39. Majumder, K., Wu, J., Molecular targets of antihypertensive peptides: Understanding the mechanisms of action based on the pathophysiology of hypertension. International Journal of Molecular Sciences 16:1 (2014), 256–283.
40. Martins, M.B., Carvalho, I., Diketopiperazines: Biological activity and synthesis. Tetrahedron 63 (2007), 9923–9932.
41. McEver, R.P., Leukocyte-endothelial cell interactions. Current Opinion in Cell Biology 4 (1992), 840–849.
42. Miguel, M., Alvarez, Y., López-Fandiño, R., Alonso, M.J., Salaices, M., Vasodilator effects of peptides derived from egg white proteins. Regulatory Peptides 140 (2007), 131–135.
43. Miguel, M., López-Fandiño, R., Ramos, M., Aleixandre, A., Short-term effect of egg white hydrolysate products on the arterial blood pressure of hypertensive rats. British Journal of Nutrition 94 (2005), 731–737.
44. Mohan, A., Udechukwu, M.C., Rajendran, S.R., Udenigwe, C.C., Modification of peptide functionality during enzymatic hydrolysis of whey proteins. RSC Advances 5 (2015), 97400–97407.
45. Münzel, T., Sinning, C., Post, F., Warnholtz, A., Schulz, E., Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Annals of Medicine 40 (2008), 180–196.
46. Nakamura, T., Hirota, T., Mizushima, K., Ohki, K., Naito, Y., Yamamoto, N., et al. Milk-derived peptides, Val-Pro-Pro and Ile-Pro-Pro, attenuate atherosclerosis development in apolipoprotein E-deficient mice: A preliminary study. Journal of Medicinal Food 16 (2013), 396–403.
47. Nakamura, Y., Yamamoto, N., Sakai, K., Takano, T., Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-Converting enzyme. Journal of Dairy Science 78 (1995), 1253–1257.
48. Prada, J.A.H., Ferreira, A.J., Katovich, M.J., Shenoy, V., Qi, Y., Santos, R.A.S., et al. Structure-based identification of small molecule angiotensin converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51 (2008), 1312–1317.
49. Quirós, A., Dávalos, A., Lasunción, M.A., Ramos, M., Recio, I., Bioavailability of the antihypertensive peptide LHLPLP: Transepithelial flux of HLPLP. International Dairy Journal 18 (2008), 279–286.
50. Ringseis, R., Gotze, V., Eder, K., Tripeptides from dietary proteins inhibit TNF alpha-induced monocyte adhesion to human aortic endothelial cells. Regulatory Peptides 154 (2009), 91–96.
51. Sánchez-Rivera, L., Martínez-Maqueda, D., Cruz-Huerta, E., Miralles, B., Recio, I., Peptidomics for discovery, bioavailability and monitoring of dairy bioactive peptides. Food Research International 63 (2014), 170–181.
52. Santos, R.A.S., Silva, A.C.S., Maric, C., Silva, D.M.R., Machado, R.P., Buhr, I., et al. Angiotensin-(1-7) is an endogenous ligand for thr G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences 100 (2003), 8258–8263.
53. Sarzani, R., Salvi, F., Dessi-Fulgheri, P., Rappelli, A., Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: An integrated view in humans. Journal of Hypertension 26 (2008), 831–843.
54. Sattar, N., Inflammation and endothelial dysfunction: Intimate companions in the pathogenesis of vascular disease?. Clinical Science 106 (2004), 443–445.
55. Schulz, E., Anter, E., Keaney, J.F. Jr., Oxidative stress, antioxidants, and endothelial function. Current Medicinal Chemistry 11 (2004), 1093–1104.
56. Schulz, E., Gori, T., Münzel, T., Oxidative stress and endothelial dysfunction in hypertension. Hypertension Research 34 (2011), 665–673.
57. Segura-Campos, M., Chel-Guerrero, L., Betancur-Ancona, D., Hernandez-Escalante, V.M., Bioavailability of bioactive peptides. Food Reviews International 27 (2011), 213–226.
58. Sipola, M., Finchenberg, P., Vapaatalo, H., Korhonen, H., Nurminen, M.L., α-lactorphin and β-lactorphin improve arterial function in spontaneously hypertensive rats. Life Sciences 71 (2002), 1245–1253.
59. Udenigwe, C.C., Aluko, R.E., Food protein-derived bioactive peptides: Production, processing, and potential health benefits. Journal of Food Science 77 (2012), R11–R24.
60. Udenigwe, C.C., Mohan, A., Mechanisms of food protein-derived antihypertensive peptides other than ACE inhibition. Journal of Functional Foods 8 (2014), 45–52.
61. Van Lancker, F., Adams, A., De Kimpe, N., Chemical modifications of peptides and their impact on food properties. Chemical Reviews 111 (2011), 7876–7903.
62. Vanhoutte, P.M., Endothelium and control of vascular function: State of the art lecture. Hypertension 13 (1989), 658–667.
63. Vermeirssen, V., Van Camp, J., Verstraete, W., Bioavailability of angiotensin I converting enzyme inhibitory peptides. British Journal of Nutrition 92 (2004), 357–366.
64. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme related carboxypeptidase. The Journal of Biological Chemistry 277 (2002), 14838–14843.
65. Yamaguchi, N., Kawaguchi, K., Yamamoto, N., Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. European Journal Pharmacology 620 (2009), 71–77.
66. Yang, Z., Yu, X., Cheng, L., Miao, L., Li, H., Han, L., et al. Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats. Archives of Cardiovascular Diseases 106 (2013), 196–201.
67. Yoshikawa, M., Tani, F., Shiota, A., Suganuma, H., Usui, H., Kurahashi, K., et al. Casoxin D, an opioid antagonist/ileum-contracting/vasorelaxing peptide derived from human αs1-casein. Brantl, V., Teschemacher, H., (eds.) β-Casomorphins and related peptides: Recent developments. (pp.43–48), 1994, VCH-Weinheim, Germany.
68. Yoshikawa, M., Tani, F., Yoshimura, T., Chiba, H., Opioid peptides from milk proteins. Agricultural and Biological Chemistry 50 (1986), 2419–2421.
69. Zhao, R.Z., Chen, X., Yao, Q., Chen, C., TNF-alpha induces interleukin-8 and endothelin-1 expression in human endothelial cells with different redox pathways. Biochemical and Biophysical Research Communications 327 (2005), 985–992.
70. Zhong, J., Basu, R., Guo, D., Chow, F.L., Byrns, S., Schuster, M., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728.
71. Zhong, J., Huang, D., Yang, Y., Li, Y., Liu, G., Song, H., et al. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acids in spontaneously hypertensive rats. Hypertension 44 (2004), 907–912.
72. Zhong, J., Ye, J., Jin, H., Yu, X., Yu, H., Zhu, D., et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regulatory Peptides 166 (2011), 90–97.
73. Zhuo, J.L., Ferrao, F.M., Zheng, Y., Li, X.C., New frontiers in the intrarenal renin-angiotensin system: A critical review of classical and new paradigms. Frontiers in Endocrinology, 4, 2013, 166.